Brought to you by 
R-Pharm licenses Theravance’s antibiotic programs in CIS region
25 Jul 2014
Executive Summary
Russian finished drug and API manufacturer R-Pharm has licensed exclusive development and commercialization rights in the CIS countries to Theravance Inc.’s Vibativ (telavancin), a lipoglycopeptide for complicated skin and soft tissue infections (cSSSIs) caused by gram-positive bacteria including methicillin-resistant S. aureus (MRSA), and TD1792, a glycopeptide-cephalosporin heterodimer antibiotic candidate.
Deal Industry
- Biotechnology
- Pharmaceuticals
Deal Status
- Final
Deal Type
-
Alliance
- Includes Royalty or Profit Split Information
- R&D and Marketing (Licensing)
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
R-Pharm licenses Theravance’s antibiotic programs in CIS region
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice